Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-3441cbef7f1604451bb170e82be4a4ea"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-3441cbef7f1604451bb170e82be4a4ea"/>
<resource>
<Composition>
<id value="composition-en-3441cbef7f1604451bb170e82be4a4ea"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-3441cbef7f1604451bb170e82be4a4ea"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-3441cbef7f1604451bb170e82be4a4ea</b></p><a name="composition-en-3441cbef7f1604451bb170e82be4a4ea"> </a><a name="hccomposition-en-3441cbef7f1604451bb170e82be4a4ea"> </a><a name="composition-en-3441cbef7f1604451bb170e82be4a4ea-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1000/001-002 (blister)</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - jinarc</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1000/001-002 (blister)"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp3441cbef7f1604451bb170e82be4a4ea"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - jinarc"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Jinarc is and what it is used for</li><li>What you need to know before you take Jinarc</li><li>How to take Jinarc</li><li>Possible side effects</li><li>How to store Jinarc</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What jinarc is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What jinarc is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Jinarc contains the active substance tolvaptan which blocks the effect of vasopressin, a hormone involved in the formation of cysts in the kidneys of ADPKD patients. By blocking the effect of vasopressin, Jinarc slows the development of kidney cysts in patients with ADPKD, reduces symptoms of the disease and increases urine production.</p><p>Jinarc is a medicine used to treat a disease called autosomal dominant polycystic kidney disease<br/>(ADPKD). This disease causes growth of fluid-filled cysts in the kidneys, which put pressure on surrounding tissues and reduce kidney function, possibly leading to kidney failure. Jinarc is used to treat ADPKD in adults with chronic kidney disease (CKD) stages 1 to 4 with evidence of rapidly progressing disease.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take jinarc"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take jinarc"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Jinarc</p><ul><li>if you are allergic to tolvaptan or any of the other ingredients of this medicine (listed in section 6) or if you are allergic to benzazepine or benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine)</li><li>if you have been told that you have raised levels of liver enzymes in your blood which do not allow treatment with tolvaptan</li><li>if your kidneys do not work (no urine production)</li><li>if you have a condition which is associated with a very low blood volume (e.g. severe dehydration or bleeding)</li><li>if you have a condition which increases the sodium in your blood</li><li>if you do not realise when you are thirsty</li><li>if you are pregnant</li><li>if you are breastfeeding.</li></ul><p>Warnings and precautions Talk to your doctor before taking Jinarc</p><ul><li>if you suffer from liver disease.</li><li>if you cannot drink enough water (see drinking enough water below) or if you have to restrict your fluid intake.</li><li>if you have difficulties urinating (e.g. have an enlarged prostate).</li><li>if you suffer from too high or too low blood sodium.</li><li>if you had an allergic reaction in the past to benzazepine, tolvaptan or other benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine), or to any of the other ingredients of this medicine (listed in section 6).</li><li>if you have diabetes.</li><li>if you have been told you have high levels of a chemical called uric acid in your blood (which may have caused attacks of gout).</li><li>if you have advanced kidney disease.</li></ul><p>This medicine may cause your liver to not work properly. Therefore, please inform your doctor immediately if you have signs that could indicate potential liver problems such as:</p><ul><li>nausea</li><li>vomiting</li><li>fever</li><li>tiredness</li><li>loss of appetite</li><li>pain in the abdomen</li><li>dark urine</li><li>jaundice (yellowing of skin or eyes)</li><li>itching of your skin</li><li>flu-like syndrome (joint and muscle pain with fever)</li></ul><p>During treatment with this medicine, your doctor will arrange monthly blood tests to check for changes in your liver function.</p><p>Drinking enough water</p><p>This medicine causes water loss because it increases your urine production. This water loss may result in side effects such as dry mouth and thirst or even more severe side effects like kidney problems (see section 4). It is therefore important that you have access to water and that you are able to drink sufficient amounts when you feel thirsty. Before bed-time you must drink 1 or 2 glasses of water even if you do not feel thirsty and you must also drink water after you urinate at night. Special care must be taken if you have a disease that reduces appropriate fluid intake or if you are at an increased risk of water loss e.g. in case of vomiting or diarrhoea. Due to the increased urine production, it is also important that you always have access to a toilet.</p><p>Children and adolescents Do not give this medicine to children and adolescents (under age of 18 years) because it has not been studied in these age groups.</p><p>Other medicines and Jinarc Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>The following medicines may increase the effect of Jinarc:</p><ul><li>amprenavir, atazanavir, darunavir/ritonavir and fosamprenavir (used to treat HIV/AIDS),</li><li>aprepitant (used to avoid nausea and vomiting in chemotherapy),</li><li>crizotinib and imatinib (used to treat cancer),</li><li>ketoconazole, fluconazole or itraconazole (used to treat fungal infections),</li><li>macrolide antibiotics like erythromycin or clarithromycin,</li><li>verapamil (used to treat heart diseases and high blood pressure),</li><li>ciprofloxacin (an antibiotic),</li><li>diltiazem (used to treat high blood pressure and chest pain).</li></ul><p>The following medicines may lower the effect of Jinarc:</p><ul><li>phenytoin or carbamazepine (used to treat epilepsy),</li><li>rifampicin, rifabutin or rifapentine (used to treat tuberculosis),</li><li>St. John s Wort (a traditional herbal medicinal product for the relief of slightly low mood and mild anxiety).</li></ul><p>Jinarc may increase the effect of the following medicines:</p><ul><li>digoxin (used to treat irregular heart beat and heart failure),</li><li>dabigatran (used to thin the blood),</li><li>sulfasalazine (used to treat inflammatory bowel disease or rheumatoid arthritis),</li><li>metformin (used to treat diabetes).</li></ul><p>Jinarc may lower the effect of the following medicines:</p><ul><li>vasopressin analogues such as desmopressin (used to increase blood clotting factors or to control urine output or bedwetting).</li></ul><p>These medicines can affect or be affected by Jinarc:</p><ul><li>diuretics (used to influence the production of urine). Taken with Jinarc these may increase the risk of side effects due to water loss or may cause kidney problems.</li><li>diuretics or other medicines for the treatment of high blood pressure. Taken with Jinarc these may increase the risk of low blood pressure when you stand up from sitting or lying down.</li><li>medicines which increase the level of sodium in your blood or which contain large amounts of salt (e.g. tablets that dissolve in water and indigestion remedies). These may increase the effect of Jinarc. There is a risk that this may lead to too much sodium in your blood.</li></ul><p>It may still be alright for you to take these medicines and Jinarc together. Your doctor will be able to decide what is suitable for you.</p><p>Jinarc with food and drink Do not drink grapefruit juice when taking this medicine.</p><p>Pregnancy and breast-feeding Do not take this medicine if you are pregnant or breast-feeding. Women of childbearing age must use reliable contraceptive measures during use of this medicine. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Driving and using machines Some people may feel dizzy, weak or tired after being given Jinarc. If this happens to you, do not drive or use any tools or machines.</p><p>Jinarc contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p></div>
</text>
</section>
<section>
<title value="3. How to take jinarc"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take jinarc"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Jinarc can only be prescribed by doctors who are specialised in the treatment of ADPKD. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Dose</p><p>The daily amount of Jinarc is split into two doses, one bigger than the other. The higher dose should be taken in the morning when you wake up, at least 30 minutes before the morning meal. The lower dose is taken 8 hours later.</p><p>The dose combinations are: 45 mg + 15 mg 60 mg + 30 mg 90 mg + 30 mg</p><p>Your treatment will normally start with a dose of 45 mg in the morning and 15 mg 8 hours later. Your doctor may gradually increase your dose up to a maximum combination of 90 mg on waking and 30 mg after 8 hours. To find the best dose your doctor will regularly check how well you are tolerating a prescribed dose. You should always take the highest tolerable dose combination prescribed by your doctor.</p><p>If you take other medicines, which can increase the effects of Jinarc you may receive lower doses. In this case your doctor may prescribe you Jinarc tablets with 30 mg or 15 mg tolvaptan which have to be taken once a day in the morning.</p><p>Method of administration</p><p>Swallow the tablets without chewing, with a glass of water. The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can be taken with or without food.</p><p>If you take more Jinarc than you should If you have taken more tablets than your prescribed dose, drink plenty of water and contact your doctor or your local hospital immediately. Remember to take the medicine pack with you so that it is clear what you have taken. If you take the higher dose very late in the day you may have to go to the toilet at night more frequently.</p><p>If you forget to take Jinarc If you forget to take your medicine, you should take the dose as soon as you remember on the same day. If you do not take your tablets on one day, take your normal dose on the next day. DO NOT take a double dose to make up for forgotten individual doses.</p><p>If you stop taking Jinarc If you stop taking this medicine your kidney cysts may grow as fast as they did before you started treatment with Jinarc. Therefore, you should only stop taking this medicine if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects:</p><p>If you notice any of the following side effects, you may need urgent medical attention. Stop taking Jinarc and immediately contact a doctor or go to the nearest hospital if you:</p><ul><li>find it difficult to urinate.</li><li>experience swelling of the face, lips or tongue, itching, generalised rash, or severe wheezing or breathlessness (symptoms of an allergic reaction).</li></ul><p>Jinarc may cause your liver not to work properly. Consult your doctor if symptoms of nausea, vomiting, fever, tiredness, loss of appetite, pain in the abdomen, dark urine, jaundice (yellowing of skin or eyes), itching of your skin or joint and muscle pain with fever occur.</p><p>Other side effects:</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>thirst (requiring excessive drinking of water)</li><li>headache</li><li>dizziness</li><li>diarrhoea</li><li>dry mouth</li><li>increased need to urinate, to urinate at night, or to urinate more frequently</li><li>fatigue</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>dehydration</li><li>high levels of sodium, uric acid and blood sugar</li><li>decreased appetite</li><li>taste changes</li><li>gout</li><li>difficulty sleeping</li><li>fainting</li><li>heart pounding</li><li>shortness of breath</li><li>belly pain</li><li>full or bloated or uncomfortable feeling in the stomach</li><li>constipation</li><li>heartburn</li><li>liver function abnormal</li><li>dry skin</li><li>rash</li><li>itching</li><li>hives</li><li>joint pain</li><li>muscle spasms</li><li>muscle pain</li><li>general weakness</li><li>raised levels of liver enzymes in the blood</li><li>weight loss</li><li>weight gain</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>increase of bilirubin (a substance that can cause yellowing of skin or eyes) in the blood</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>allergic reactions (see above)</li><li>generalised rash</li><li>acute liver failure (ALF)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store jinarc"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store jinarc"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date, which is stated on the carton, wallet card and the blister after EXP. The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from light and moisture.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Jinarc contains</p><ul><li><p>The active substance is tolvaptan. Each Jinarc 15 mg tablet contains 15 mg tolvaptan. Each Jinarc 30 mg tablet contains 30 mg tolvaptan. Each Jinarc 45 mg tablet contains 45 mg tolvaptan. Each Jinarc 60 mg tablet contains 60 mg tolvaptan. Each Jinarc 90 mg tablet contains 90 mg tolvaptan.</p></li><li><p>The other ingredients are lactose monohydrate (see section 2), maize starch, microcrystalline cellulose, hydroxypropylcellulose, magnesium stearate, indigo carmine aluminium lake.</p></li></ul><p>What Jinarc looks like and contents of the pack</p><p>The different strengths of Jinarc tablets have different shapes and embossing: 15 mg tablet: blue, triangular, debossed with OTSUKA and 15 on one side. 30 mg tablet: blue, round, debossed with OTSUKA and 30 on one side. 45 mg tablet: blue, square, debossed with OTSUKA and 45 on one side 60 mg tablet: blue, modified rectangular, debossed with OTSUKA and 60 on one side 90 mg tablet: blue, pentagonal, debossed with OTSUKA and 90 on one side</p><p>Your medicine is supplied in the following pack sizes:</p><p>Jinarc 15 mg tablets: packs containing 7 tablets or 28 tablets</p><p>Jinarc 30 mg tablets: packs containing 7 tablets or 28 tablets</p><p>Jinarc 45 mg tablets + Jinarc 15 mg tablets: packs (blisters with or without wallet card) containing 14 tablets (7 tablets of the higher strength + 7 tablets of the lower strength), 28 tablets (14 tablets of the higher strength + 14 tablets of the lower strength) or 56 tablets (28 tablets of the higher strength + 28 tablets of the lower strength).</p><p>Jinarc 60 mg tablets + Jinarc 30 mg tablets: packs (blisters with or without wallet card) containing 14 tablets (7 tablets of the higher strength + 7 tablets of the lower strength), 28 tablets (14 tablets of the higher strength + 14 tablets of the lower strength) or 56 tablets (28 tablets of the higher strength + 28 tablets of the lower strength).</p><p>Jinarc 90 mg tablets + Jinarc 30 mg tablets: packs (blisters with or without wallet card) containing 14 tablets (7 tablets of the higher strength + 7 tablets of the lower strength), 28 tablets (14 tablets of the higher strength + 14 tablets of the lower strength) or 56 tablets (28 tablets of the higher strength + 28 tablets of the lower strength).</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>Otsuka Pharmaceutical Netherlands B.V. Herikerbergweg 1101 CT, Amsterdam Netherlands</p><p>Manufacturer</p><p>Almac Pharma Services (Ireland) Limited Finnabair Industrial Estate, Dundalk, Co. Louth - A91 P9KD Ireland</p><p>Millmount Healthcare Limited Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YDIreland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Otsuka Pharmaceutical Netherlands B.V. T l/Tel: +31 (0) 20 85 46 Lietuva Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46<br/>Otsuka Pharmaceutical Netherlands B.V. Te : +31 (0) 20 85 46 Luxembourg/Luxemburg Otsuka Pharmaceutical Netherlands B.V. T l/Tel: +31 (0) 20 85 46 esk republika Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Magyarorsz g Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Danmark Otsuka Pharma Scandinavia AB Tlf: +46 (0) 8 545 286 Malta Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Deutschland Otsuka Pharma GmbH Tel: +49 (0) 69 1700 Nederland Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Eesti Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Norge Otsuka Pharma Scandinavia AB Tlf: +46 (0) 8 545 286<br/>Otsuka Pharmaceutical Netherlands B.V. Th : +31 (0) 20 85 46 sterreich Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Espa a Otsuka Pharmaceutical S.A Tel: +34 (0) 93 208 1Polska Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 France Otsuka Pharmaceutical France SAS T l: +33 (0) 1 47 08 00 Portugal Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Hrvatska Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Rom nia Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Ireland Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Slovenija Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 sland Otsuka Pharma Scandinavia AB S mi: +46 (0) 8 545 286 Slovensk republika Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 Italia Otsuka Pharmaceutical Italy S.r.l. Tel: +39 (0) 2 0063 2Suomi/Finland Otsuka Pharma Scandinavia AB Puh/Tel: +46 (0) 8 545 286<br/>Otsuka Pharmaceutical Netherlands B.V. Th : +31 (0) 20 85 46 Sverige Otsuka Pharma Scandinavia AB Tel: +46 (0) 8 545 286 Latvija Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 United Kingdom (Northern Ireland) Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp3441cbef7f1604451bb170e82be4a4ea"/>
<resource>
<MedicinalProductDefinition>
<id value="mp3441cbef7f1604451bb170e82be4a4ea"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp3441cbef7f1604451bb170e82be4a4ea"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp3441cbef7f1604451bb170e82be4a4ea</b></p><a name="mp3441cbef7f1604451bb170e82be4a4ea"> </a><a name="hcmp3441cbef7f1604451bb170e82be4a4ea"> </a><a name="mp3441cbef7f1604451bb170e82be4a4ea-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1000/001-002 (blister)</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Jinarc 15 mg tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1000/001-002 (blister)"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Jinarc 15 mg tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
